Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 1.00 |
| ▸ | PGR | P06401 | 17/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572805 | 1.00 | AR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12998970 | 1.00 | AR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL16572820 | 1.00 | AR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12942954 | 1.00 | AR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12998916 | 0.90 | AR (0.82) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12998973 | 0.89 | PGR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12998957 | 0.89 | PGR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12943026 | 0.89 | PGR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL16572803 | 0.89 | PGR (1.00) | ARPGRLMNAABCC4ABCB11 | |
| SCHEMBL12942952 | 0.88 | AR (0.78) | ARPGRLMNAABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER SCHERING PHARMA AKTEINGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | AR 58/4885PGR 57/4885LMNA 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.